Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: A cardiovascular magnetic resonance study

Heart

Volumn 90, Issue 7, 2004, Pages 760-764

  Bellenger, N G ^a   Rajappan, K ^a   Rahman, S L ^a   Lahiri, A ^b   Raval, U ^b   Webster, J ^a   Murray, G D ^c   Coats, A J S ^a   Cleland, J G F ^d   Pennell, D J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE CONTRACTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

EID: 3042687447     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.015552     Document Type: Article

References (44)

1. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol 1995;25:1225-31.
2. Packer M, Bristow MR, Cohn JN, et al, for the US carvedilol heart failure study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-5.
3. Australia/New Zealand Heart Failure research Collaborative Group. Effects of carvedilol in patients with congestive heart failure due to ischaemic heart disease: final results from the ANZ heart failure research collaborative trial. Lancet 1997;349:212-18.
4. Waagstein F, Bristow MR, Swedberg K, et al, for the Metoprolol in Dilated Cardiomyopathy trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
5. CIBIS Investigators and Committees. A randomised trial of B-blockade in heart failure: the cardiac insufficiency bisoprolol study. Circulation 1994;90:1765-73.
6. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomised comparison of effect of long term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure. Circulation 1999;99:2645-51.
7. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia-New Zealand heart failure research collaborative group. J Am Coll Cardiol 1997;29:1060-6.
8. Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999;138:460-7.
9. Bellenger NG, Davies LC, Francis JM, et al. Reduction in sample size for studies of remodelling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000;2:271-8.
10. Grothues F, Smith GS, Bellenger NG, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance and 2D echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90:29-34.
11. Cleland JGF, Pennell DJ, Ray S, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003;362:14-21.
12. Pennell DJ, Ray SG, Davies G, et al. The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. Int J Cardiol 2000;72:265-74.
13. Bellenger NG, Francis JM, Davies LC, et al. Establishment and performance of a magnetic resonance cardiac function clinic. J Cardiovasc Mag Reson 1999;4:323-30.
14. Katz J, Milliken MC, Stray-Gundersen J, et al. Estimation of human myocardial mass with MR imaging. Radiology 1888;169:495-8.
15. Schwammenthal E, Wichter T, Joachimsen K, et al. Detection of regional left ventricular asynchrony in obstructive hypertrophic cardiomyopothy by magnetic resonance imaging. Am Heart J 1994;127:600-6.
16. Lorenz CH, Walker ES, Morgan VL, et al. Normal human right and left ventricular mass, systolic function and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1999;1:7-21.
17. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
18. McKee PA, Castell WP, Mcnamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-5.
19. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998;31:1635-40.
20. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular function in heart failure: results of a meta-analysis. Am Heart J 2001;141:884-8.
21. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
22. Metra ML, Giubbini R, Nodari S, et al. Differential effects of beta blockers in patients with heart failure. A prospective, randomised, double-blind comparison of the long term effects of metoprolol versus carvedilol. Circulation 2000;102:546-51.
23. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
24. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
25. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793-9.
26. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
27. Cohn JN, Fowler MB, Bristow MB, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997;3:173-9.
28. Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a fallow up of patients with congestive cardiac failure treated with carvedilol. Am Heart J 1999;138:460-7.
29. DiLenarda A, Sabbadini G, Salvatore L, et al. Long term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999;33:1926-34.
30. Sanderson JE, Chan SKW, Yip G, et al. Beta blockade in heart failure. A comparison of carvedilol with metroprolol. J Am Coll Cardiol 1999;34:1522-8.
31. Engelmeimer RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomypathy: a double blind, randomised, placebo controlled trial. Circulation 1985;72:536-46.
32. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in dilated cardiomypathy. Lancet 1993;342:1441-6.
33. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomised trial. J Am Coll Cardiol 1994;23:943-50.
34. Goldstein S, Kennedy HL, Hall C, et al. Metoprolol CR/XL in patients with heart failure; a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Am Heart J 1999;138:1158-65.
35. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischaemic and dilated cardiomyopathy. The randomised evaluation of strategies for left ventricular pilot study. Circulation 2000;101:378-84.
36. Sharpe N, Doughty RN. Left ventricular remodelling and improved long-term outcomes in chronic heart failure. Eur Heart J 1998;19(suppl B):B36-9.
37. Khattar RS, Senior R, Soman P, et al. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. Am Heart J 2001;142:704-13.
38. Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodelling effects on left entricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-80.
39. Dubach P, Myers J, Bonetti P, et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J 2002;143:676-83.
40. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12-22C.
41. Gilbert EM, Abraham AT, Olsen S, et al. Comparative hemodynamic, LV functional, and anti-adrenergic effects of chronic treatment with metoprolol vs carvedilol in the failing heart. Circulation 1996;94:2817-25.
42. Heilbrunn SM, Shah P, Bristow MR, et al. Increased b-receptor density and improved response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomypathy. Circulation 1989;79:483-90.
43. Bristow MR, Larrabee P, Muller-Beckmann B, et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 1992;70:S105-13.
44. Metra M, Nardi M, Giubbini R, et al. Effects of short and long term carvedilol administration on rest and exercise haemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.